Skip to content
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Envoy Medical, Inc. COCH

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$241,000
▲ 7.1% YoY
$-23.8M
$-18.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Our first product, the Esteem FI-AMEI, received FDA approval in 2010. The Esteem FI-AMEI remains the only FDA approved fully implanted active hearing implant on the market. In late 2015, we made the decision to shift our focus from the Esteem FI-AMEI to a new product that would leverage our sensor technology and incorporate it into a cochlear implant. The Acclaim CI is fully implanted and does not have the need for any external component to be worn on the ear. The Acclaim CI received the Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2019.

Written from the business description in Envoy Medical, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 March 2026. Every sentence was checked against that document before publication.

Growth

USD 241,000.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.2 · Net income -23.8
-15M-30M
202120242025
Compound annual growth
+0.6%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -9240.7%
-5000%
202120232025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

USD 1.8M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.4
-10M-20M
202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends 1.8 · Net buybacks ·
1M2M
20242025

USD 1.8M in dividends went back to shareholders in a year without profit.

Total assetsUSD 8.6M
EquityUSD -12.2M
CashUSD 3.7M
Current ratio0.54×

Equity funds -142% of total assets.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
COCH, 5-year financial record
Metric 20252024202320222021
Revenue $B0.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0◌
Income tax $B◌◌◌0.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0◌
EPS, diluted $−1.23−1.49−2.54−1.57◌
Dividend / sh $◌◌◌◌◌
Payout %−8−12———
ROE % — not applicable: negative equity—————
Shares out B◌◌0.02◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 19 reconciliationsAUDITED

Reconciled in 5 of the 5 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 15 checks were skipped: the share count is not tagged before 2022. 15 checks were skipped: revenue is not tagged before 2022.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image